Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats

Human and Experimental Toxicology

Volumn 30, Issue 2, 2011, Pages 102-109

  Rashikh, Azhar ^a   Abul Kalam Najmi, ^a   Akhtar, Mohammad ^a   Mahmood, Danish ^a   Pillai, Krishna K ^a   Ahmad, Shibli J ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

aliskiren; cardiomyopathy; cardiotoxicity; doxorubicin; renin inhibitor

Indexed keywords

ALISKIREN; CHOLESTEROL; DOXORUBICIN; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

AMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; FUMARATES; LIPID PEROXIDATION; LIPIDS; MYOCARDIUM; RATS; RATS, WISTAR; RENIN; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA; RATTUS;

EID: 79551535266     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110369819     Document Type: Article

References (41)

1. Gianni L., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity in breast cancer patients. Synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007 ; 7: 67-71.
2. Bryant J., Picot J., Levitt G., Sullivan I., Baxter L., Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Tech Assess 2007 ; 11: 1-102.
3. Kumar D., Kirshenbaum LA, Danelisen I., Singal PK Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001 ; 3: 135-145.
4. Wallace KB Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovascular Toxicology 2007 ; 7: 101-107.
5. Sawyer DB, Fukazawa R., Arstall MA Daunorubicininduced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999 ; 84: 257-265.
6. Jensen BV, Nielsen SL, Jensen TS Angiotensinconverting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy. Ugeskr Laeger 1997 ; 159 (13). 1945-1949.
7. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensinconverting- enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996 ; 347: 297-299. (Pubitemid 26041043)
8. Baker KM, Booz GW, Dostal DE Cardiac actions of angiotensin II: role of an intracardiac rennin-angiotensin system. Ann Rev Physiol 1992 ; 54: 227-241.
9. Dunn FG, Oigman W., Ventura HO, Messeri FH, Kobrin I., Frohlich ED Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984 ; 53: 105-108.
10. Gradman AH, Schmieder RE, Lins RL Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 ; 111: 1012-1018.
11. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000 ; 52: 11-34.
12. Nussberger J., Wuerzner G., Jensen C., Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002 ; 39: E1 - E8.
13. Iqbal M., Dubey K., Anwer T., Ashish A., Pillai KK Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008 ; 60: 382-390.
14. Luft CF Achieving the goal of optimized renin system suppression: preclinical experience with a direct renin inhibitor. J Renin Angiotensin Aldosterone Sys 2006 ; 7: S12 - S15.
15. Lum G., Gambino SR A comparison of serum versus heparinised plasma for routine chemistry tests. Am J Clin Pathol 1974 ; 61: 108.
16. Wybenga DR, Pileggi VJ, Dirstine PH, Giorgio JD Direct manual determination of serum total cholesterol with a single stable reagent. Clin Chem 1970 ; 16: 980-984.
17. Stein A., Mayer GL National Cholesterol Education Program Recommendations for the Triglycerides Measurement: Executive Summary. Clin Chem 1995 ; 41: 1421-1426.
18. Ohkawa H., Oshishi N., Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem 1979 ; 95: 351-358.
19. Lowry OH, Rosenburg NJ, Farr AL, Randall RJ Protein measurement with Folin phenol reagent. J Biol Chem 1951 ; 193: 265-275.
20. Sedlack J., Lindsay RH Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968 ; 25: 192-205.
21. Belur B., Kandaswamy N., Mukherjee KL Laboratory technology - a procedure manual for routine diagnostic tests. Delhi, India: Tata Mc Graw Hill Co. Ltd, 1990, p. 1124-118.
22. Steinherz LJ, Steinherz PG, Tan CC, Heller G., Murphy L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 1991 ; 266: 1672-1677.
23. Myers CE The role of free radical damage in the genesis of doxorubicin cardiac toxicity. In: Muggia FM, Young CW, Carters K (eds.) Anthracycline antibiotics in cancer chemotherapy The Hague: Martinus Nijhoff, 1982, 297-305.
24. Doroshow JH Effect of anthracycline antibiotics on oxygen free radical formation in rat heart. Cancer Res 1983 ; 43: 460-472.
25. Singal PK, Deally CM, Weinberg LE Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987 ; 19: 817-828.
26. Yin X., Wu H., Chen Y., Kang YJ Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998 ; 56: 87-93.
27. Porta EA, Joun NS, Matsumura L., Nakasone B., Sablan H. Acute adriamycin cardiotoxicity in rats. Res Comm Chem Pathol Pharmacol 1983 ; 41: 125-137.
28. Clement DL, De Buyzere ML, De Bacquer. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. New Engl J Med 2003 ; 24: 2407-2415.
29. Fleetwood G., Boutinet S., Meier M., Wood JM Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol 1991 ; 17: 351-356.
30. Li K., Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987 ; 19: 909-915.
31. Weber KT, Brilla CG Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin- aldosterone system. Circulation 1991 ; 83: 1849-1865.
32. Buyukokuroglu ME, Taysi S., Buyukavci M., Bakan E. Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. Hum Exp Toxicol 2004 ; 23: 251-256.
33. Fadillioglu E., Erodogen H., Sogut S., Kuku I. Protective effects of erdosteine against doxorubicin induced cardiomyopathy in rats. J Appl Toxicol 2003 ; 23: 71-74.
34. Lefrak EA, Pitha J., Rosenheim S., Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 1973 ; 32: 302-314.
35. Siveski-Iliskovic N., Hill M., Chow DA Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995 ; 91: 10-15.
36. Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chem Biol Interact 2003 ; 146: 201-210.
37. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1998 ; 339: 900-905.
38. Myers CE, McGuire WP, Liss RH, Ifrim I., Grotzinger K., Young RC Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977 ; 197: 165-167.
39. Saad SY, Najjar TA, Al-Rikabi AC The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001 ; 43: 211-218.
40. Yilmaz S., Atessahin A., Sahna E., Karan I., Ozers S. Protective effect of lycopen on adriamycin-induced cardiotoxicity, nephrotoxicity. Toxicology 2006 ; 218: 164-171.
41. Dinesh M Parmar, Jadav SP Letter to the editor. Aliskiren: a novel renin inhibitor for hypertension. Ind J Physiol Pharmacol 2007 ; 51: 99-101.